CNS penetration of the CDK4/6 inhibitor ribociclib in non-tumor bearing mice and mice bearing pediatric brain tumors

ConclusionsThe CNS penetration observed was encouraging enough to move ribociclib forward with preclinical efficacy studies in models of pediatric brain tumors.

Source: Cancer Chemotherapy and Pharmacology - July 15, 2019 Category: Cancer & Oncology Source Type: research